Researchers developed optimized RD1 and RD2 peptide pools designed to broaden detection of antigen-specific interferon-gamma T-cell responses in clinical tuberculosis samples. The approach aims to improve assay sensitivity and coverage compared with older peptide designs that may miss certain response patterns. For diagnostics and vaccine studies, better immunogenicity readouts can translate into cleaner comparisons across patient populations and clinical protocols. The work also supports more robust monitoring of TB antigen-specific cellular immunity in downstream translational programs.